Ligand Pharmaceuticals (LGND) Non-cash Items (2011 - 2012)
Ligand Pharmaceuticals' (LGND) quarterly Non-cash Items came in at $6.6 million in Q2 2012, up 343.25% quarter-over-quarter from $1.5 million in Q4 2011.
Ligand Pharmaceuticals (LGND) Non-cash Items (2011 - 2012) Analysis & Trends
Ligand Pharmaceuticals has disclosed Non-cash Items across 2 years of filings, most recently posting $6.6 million for Q2 2012.
- Non-cash Items for Q2 2012 came in at $6.6 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2012 was $6.6 million (changed N/A YoY), and the FY2011 annual result was $1.5 million, changed N/A from the prior year.
- Non-cash Items came in at $6.6 million for Q2 2012 at Ligand Pharmaceuticals, up from $1.5 million in the prior quarter.
- In the past five years, Non-cash Items ranged from a high of $6.6 million in Q2 2012 to a low of $1.5 million in Q4 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ligand Pharmaceuticals | 5.47 Bn | 4.69 Bn | 48.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2012 | 6.60 Mn |
| Jun 30, 2012 | 6.60 Mn |
| Dec 31, 2011 | 1.49 Mn |
| Dec 31, 2011 | 1.49 Mn |